EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH DIABETES: RESULTS OF A SUBGROUP ANALYSIS FROM THE POLARIS STUDY

被引：0

作者：

Leiter, L. A. ^{[1
]}

Sosef, F. ^{[2
]}

Ycas, J. ^{[3
]}

Melezinkova, H. ^{[4
]}

机构：

[1] Univ Toronto, St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada

[2] AstraZeneca, Molndal, Sweden

[3] AstraZeneca, Wilmington, DE USA

[4] AstraZeneca, Macclesfield, Cheshire, England

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2008年 / 9卷 / 01期

关键词：

D O I：

10.1016/S1567-5688(08)70816-X

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：204 / 204

页数：1

共 50 条

[1] Efficacy of rosuvastatin 40 mg versus atorvastatin 80 mg in patients with the metabolic syndrome: results from a subgroup of the POLARIS study
Leiter, LA
Palmer, M
Sosef, F
DIABETOLOGIA, 2005, 48 : A392 - A392
[2] EFFICACY OF ROSUVASTATIN 10 MG VERSUS ATORVASTATIN 20 MG IN PATIENTS WITH DIABETES: SUBGROUP RESULTS FROM THE PULSAR STUDY
Clearfield, M. B.
Sosef, F.
Palmer, M.
Melezinkova, H.
ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 199 - 200
[3] Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study
Leiter, Lawrence A.
Rosenson, Robert S.
Stein, Evan
Reckless, John P. D.
Schulte, Karl-Ludwig
Schleman, Margo
Miller, Paul
Palmer, Michael
Sosef, Froukje
ATHEROSCLEROSIS, 2007, 194 (02) : E154 - E164
[4] Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: Early results of the POLARIS study
Leiter, LA
Palmer, M
Kallend, D
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 113 - 113
[5] Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: Economic analysis of the POLARIS study
Miller, PSJ
Leiter, LA
Davies, A
Sosef, F
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 114 - 114
[6] Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: results of the POLARIS study at 8 and 26 weeks
Leiter, L. A.
Palmer, M.
Sosef, F.
EUROPEAN HEART JOURNAL, 2005, 26 : 581 - 581
[7] Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses
Abate, Nicola
Catapano, Alberico L.
Ballantyne, Christie M.
Davidson, Michael H.
Polis, Adam
Smugar, Steven S.
Tershakovec, Andrew M.
JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (02) : 91 - 105
[8] Efficacy and safety of rosuvastatin 10 mg versus atorvastatin 20 mg: Results of the pulsar study
Clearfield, M
Kallend, D
Palmer, M
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 104 - 104
[9] Effect of rosuvastatin and atorvastatin on CRP levels in patients with type 2 diabetes: Results from the Andromeda Study
Betteridge, DJ
Gibson, JM
Sager, P
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 102 - 102
[10] Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: Results of the uranus study
Berne, C
Siewert-Delle, A
ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 107 - 107

← 1 2 3 4 5 →